We are live on ! Find out more
ATS icon

ATS Corp

Positive
Neutral
Negative
Sentiment 3-Months
Positive 12.5%
Neutral 62.5%
Negative 25%

Negative
Zacks Investment Research
18 days ago
New Strong Sell Stocks for June 29th
ATS, BXBLY and SKY have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2026.
New Strong Sell Stocks for June 29th
Neutral
Zacks Investment Research
25 days ago
Implied Volatility Surging for ATS Corporation Stock Options
Investors need to pay close attention to ATS stock based on the movements in the options market lately.
Implied Volatility Surging for ATS Corporation Stock Options
Neutral
GlobeNewsWire
29 days ago
Fusemachines Expands Access to Agentic AI for Talent Acquisition Through Broad ATS Connectivity
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Fusemachines Inc. (NASDAQ: FUSE), a leading provider of enterprise AI products and services, today announced expanded enterprise access to its Agentic AI for Talent Acquisition platform through new connectivity with more than 30 enterprise applicant tracking systems (ATS), enabling Fusemachines Agents to work directly within the systems organizations already use to manage talent and hiring. This expanded connectivity represents the first in a broader series of planned platform enhancements designed to bring AI-powered recruiting capabilities closer to the workflows, data, and systems recruiters rely on every day.
Fusemachines Expands Access to Agentic AI for Talent Acquisition Through Broad ATS Connectivity
Neutral
GlobeNewsWire
29 days ago
New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
Not intended for UK and US audiences  Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international congresses. Based on the modeling, nerandomilast consistently increased median survival in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).1,2 Modeling predicts meaningful extensions in survival with nerandomilast, including a multi-year increase in median survival when used as monotherapy, and additional gains when added to standard treatment.1,2 Ingelheim, Germany - Long-term survival modeling of Boehringer Ingelheim's oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis (IPF) and up to 3.3 years in adults with progressive pulmonary fibrosis (PPF), compared with no therapy.1,2 These findings are based on data from the Phase III FIBRONEER™ trials and were recently presented at the ATS and EULAR 2026 international congresses.
New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
Negative
Zacks Investment Research
1 month ago
New Strong Sell Stocks for June 15th
ATS, BFC and CMC have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2026.
New Strong Sell Stocks for June 15th
Neutral
Business Wire
1 month ago
ATS to Participate in the Stifel Summer Solstice Conference
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Anne Cybulski, Interim Chief Financial Officer, will participate in the Stifel Summer Solstice Conference in Muskoka, ON on June 16, 2026. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Stifel representative or docampo@atsautomation.com. About ATS Corporation ATS Corporation is an industry-leading automation s.
ATS to Participate in the Stifel Summer Solstice Conference
Neutral
Seeking Alpha
1 month ago
ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
Positive
MarketBeat
1 month ago
ATS Q4 Earnings Call Highlights
ATS NYSE: ATS reported higher fiscal 2026 revenue and adjusted earnings from operations, while outlining a series of restructuring actions aimed at improving margins, cash generation and capital efficiency heading into fiscal 2027.
ATS Q4 Earnings Call Highlights
Negative
Zacks Investment Research
1 month ago
ATS (ATS) Q4 Earnings Lag Estimates
ATS (ATS) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.28 per share a year ago.
ATS (ATS) Q4 Earnings Lag Estimates
Neutral
Business Wire
1 month ago
ATS Reports Fourth Quarter Fiscal 2026 Results
CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and twelve months ended March 31, 2026. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. Fourth quarter highlights: Revenues were $747.1 million (adjusted revenues1 $744.3 million) compared to $574.2 million (adjusted revenues $721.1 million) a year ago. Net loss was $16.2 million compared.
ATS Reports Fourth Quarter Fiscal 2026 Results